TG Therapeutics | TGTX - Assets


TG Therapeutics reported $1.53B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Ardelyx USD 504.51M 2.9M Mar/2026
Arrowhead Research USD 2.27B 664.08M Mar/2026
Bayer EUR 107.94B 3.4B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
Corcept Therapeutics USD 814.88M 21.77M Mar/2026
Curis USD 19.97M 9.27M Dec/2025
Gilead Sciences USD 56.28B 2.74B Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Novavax USD 1.04B 133.35M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
TG Therapeutics USD 1.53B 465.58M Mar/2026
Verastem USD 246.44M 69.59M Dec/2025
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026